Patents by Inventor Larn Hwang

Larn Hwang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nanoparticle Formulations in Biomarker Detection
    Publication number: 20150104520
    Abstract: The present invention relates to compositions and methods of treatment of cancer patients with cytotoxic drugs in particular the use of cytotoxic drugs encapsulated in a diblock copolymer formulation where the composition is stable in protein free media and less stable in protein containing media such as serum, in particular the treatment of ovarian.
    Type: Application
    Filed: April 7, 2014
    Publication date: April 16, 2015
    Inventors: Vuong Trieu, Larn Hwang
  • SPARC MICROENVIRONMENT SIGNATURE, PLASMA SPARC, AND LDH AS PROGNOSTIC BIOMARKERS IN THE TREATMENT OF CANCER
    Publication number: 20130281376
    Abstract: The invention provides multiparametric anti-SPARC antibody-based techniques for treating cancers as well as determining prognosis and predicting the response to therapy, including chemotherapy, radiotherapy, surgical therapy and combination therapies.
    Type: Application
    Filed: October 7, 2011
    Publication date: October 24, 2013
    Applicant: ABRAXIS BIOSCIENCE, LLC
    Inventors: Vuong Trieu, Larn Hwang, Kouros Motamed, Xiping Liu, Neil Desai
  • SPARC ANTISENSE COMPOSITIONS AND USES THEREOF
    Publication number: 20120183538
    Abstract: The invention provides SPARC antisense oligonucleotides and methods of their use in proliferative diseases such as cancer and hepatic fibrosis.
    Type: Application
    Filed: July 9, 2010
    Publication date: July 19, 2012
    Applicant: ABRAXIS BIOSCIENCE, LLC
    Inventors: Vuong Trieu, Larn Hwang, Neil Desai
  • ENHANCEMENT OF DRUG THERAPY BY MIRNA
    Publication number: 20090280167
    Abstract: This invention provides methods and compositions for screening of microRNA capable of modulating gene expression in the apoptotic pathway in the presence of HSP90 inhibitor. The use of miRNA for enhancing the activity of therapeutic agents not limited to HSP90 inhibitor is also disclosed. The diagnostic use of miRNA for predicting response to therapy not limited to therapeutic agents is also disclosed.
    Type: Application
    Filed: May 7, 2009
    Publication date: November 12, 2009
    Applicant: Abraxis BioScience, LLC
    Inventors: Vuong Trieu, Larn Hwang, Neil Desai
  • TREATMENT, DIAGNOSTIC, AND METHOD FOR DISCOVERING ANTAGONIST USING SPARC SPECIFIC MIRNAS
    Publication number: 20090220589
    Abstract: miRNAs that regulate human SPARC and methods of use thereof are described. Suitable nucleic acids for use in the methods and compositions described herein include, but are not limited to, pri-miRNA, pre-miRNA, ds miRNA, mature miRNA or fragments of variants thereof that retain the biological activity of the mature miRNA and DNA encoding a pri-miRNA, pre-miRNA, mature miRNA, fragments or variants thereof, or regulatory elements of the miRNA.
    Type: Application
    Filed: March 2, 2009
    Publication date: September 3, 2009
    Applicant: Abraxis BioScience, LLC
    Inventors: Vuong Trieu, Larn Hwang, Neil Desai